On May 8, 2015 GP-Pharm reported that its Lutrate Depot 22.5 mg has been approved through an EU decentralized procedure (Press release, GP Pharm, MAY 8, 2015, View Source [SID1234591045]). Lutrate Depot 22.5 mg is a new trimestral Leuprolide depot formulation for the palliative treatment of advanced prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lutrate is based on a by GP-Pharm developed patented technological platform of microspheres.
During its pivotal clinical trial phase III Lutrate Depot 22.5 mg achieved excellent castration levels in patients. Patients with prostate cancer will have the opportunity to benefit from the most effective sustained released formulation.

Lutrate Depot 22.5 mg is expected to become available in Europe during the fourth quarter of 2015.

Lutrate Depot 22.5 mg is the second Leuprolide depot formulation of GP Pharm after the successful registration of Lutrate Depot 3.75 mg in 2010 strengthens its urology and oncology portfolio.